Effects of probucol on angiotensin II-induced BMP-2 expression in human umbilical vein endothelial cells

Zhang,Ming; Wang,Jian; Liu,Jing-Hua; Chen,Shu-Juan; Zhen,Bin; Wang,Chang-Hua; He,Hua; Jiang,Chen-Xi

doi:10.3892/mmr.2012.1145

Effects of probucol on angiotensin II-induced BMP-2 expression in human umbilical vein endothelial cells

Authors:
- Ming Zhang
- Jian Wang
- Jing-Hua Liu
- Shu-Juan Chen
- Bin Zhen
- Chang-Hua Wang
- Hua He
- Chen-Xi Jiang
View Affiliations

Affiliations: Department of Cardiology, Beijing Anzhen Hospital, Capital University of Medical Sciences, Beijing 100029, P.R. China
Published online on: October 24, 2012 https://doi.org/10.3892/mmr.2012.1145
Pages: 177-182

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone morphogenetic protein-2 (BMP-2) participates significantly in vascular development and pathophysiological processes. Angiotensin II (AngII) has been demonstrated to be critical in the initiation and progression of atherosclerosis. However, the effects of AngII on BMP-2 expression and of probucol on the AngII-induced BMP-2 expression in human umbilical vein endothelial cells (HUVECs) are unknown. The aim of our study was to investigate these effects. HUVECs were cultured and stimulated with various agents. The total superoxide dismutase (SOD) activity and the concentrations of malondialdehyde (MDA) and BMP-2 were measured by standard methods. Northern blotting was used to detect the expression of BMP-2 mRNA. The activation of NF-κB in the HUVECs was also determined. The AngII treatment significantly increased BMP-2 expression levels and activated NF-κB. These effects were suppressed by treatment with pyrrolidine dithiocarbamate (PDTC) or probucol. Furthermore, the increased levels of MDA in the conditioned medium and the decrease in the total SOD activity caused by the AngII treatment were reversed by treatment with probucol or PDTC. Probucol downregulated the AngII‑induced BMP-2 expression. These effects of probucol may be mediated by the inhibition of NF-κB activation.

View Figures

View References

1	Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG and Ungvari Z: Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H₂O₂, and high intravascular pressure. Circulation. 111:2364–2372. 2005. View Article : Google Scholar : PubMed/NCBI
2	Abedin M, Tintut Y and Demer LL: Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 24:1161–1170. 2004. View Article : Google Scholar : PubMed/NCBI
3	Shanahan CM, Cary NR, Metcalfe JC and Weissberg PL: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 93:2393–2402. 1994. View Article : Google Scholar : PubMed/NCBI
4	Parhami F, Boström K, Watson K and Demer LL: Role of molecular regulation in vascular calcification. J Atheroscler Thromb. 3:90–94. 1996. View Article : Google Scholar : PubMed/NCBI
5	Hruska KA, Mathew S and Saab G: Bone morphogenetic proteins in vascular calcification. Circ Res. 97:105–114. 2005. View Article : Google Scholar : PubMed/NCBI
6	Boström KI, Jumabay M, Matveyenko A, Nicholas SB and Yao Y: Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res. 108:446–457. 2011.PubMed/NCBI
7	Libby P, Ridker PM and Maseri A: Inflammation and Atherosclerosis. Circulation. 105:1135–1143. 2002. View Article : Google Scholar : PubMed/NCBI
8	Kranzhöfer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P and Kübler W: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 19:1623–1629. 1999.PubMed/NCBI
9	Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG and Medford RM: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation. 100:1223–1229. 1999. View Article : Google Scholar : PubMed/NCBI
10	Yung LM, Wong WT, Tian XY, Leung FP, Yung LH, Chen ZY, Yao X, Lau CW and Huang Y: Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats. PLoS One. 29:e174372011. View Article : Google Scholar : PubMed/NCBI
11	Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M and Egido J: Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappaB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 95:1532–1541. 1997.
12	Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S and Hayashi J: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol. 39:610–616. 2002. View Article : Google Scholar
13	Mackness B, Durrington PN and Mackness MI: Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Commun. 247:443–446. 1998. View Article : Google Scholar : PubMed/NCBI
14	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the folin-phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
15	Oyama VI and Eagle H: Measurement of cell growth in tissue culture with a phenol reagent (Folin-Ciocalteau). Proceedings of the Society of Experimental Biology and Medicine. 91:305–307. 1956. View Article : Google Scholar : PubMed/NCBI
16	Zhang H and Bradley A: Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development. 122:2977–2986. 1996.PubMed/NCBI
17	Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V and Egido J: Inflammation and angiotensin II. Int J Biochem Cell Biol. 35:881–900. 2003. View Article : Google Scholar
18	Durante A, Peretto G, Laricchia A, Ancona F, Spartera M, Mangieri A and Cianflone D: Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des. 18:981–1004. 2012. View Article : Google Scholar : PubMed/NCBI
19	Tardif JC, Grégoire J and L’Allier PL: Prevention of restenosis with antioxidants: mechanisms and implications. Am J Cardiovasc Drugs. 2:323–334. 2002. View Article : Google Scholar : PubMed/NCBI
20	Buckley MMT, Goa KL, Price AH and Brogden RN: Probucol: a reappraisal of its pharmacological properties and therapeutic use in hypercholestecmia. Drugs. 37:761–800. 1989. View Article : Google Scholar : PubMed/NCBI
21	Tardif JC, Grégoire J, Schwartz L, Title L, Laramée L, Reeves F, Lespérance J, Bourassa MG, L’Allier PL, Glass M, Lambert J and Guertin MC; Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation. 107:552–558. 2003. View Article : Google Scholar : PubMed/NCBI
22	Kasai T, Miyauchi K, Kubota N, Kajimoto K, Amano A and Daida H: Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis. 220:463–469. 2012.
23	Traverso N, Menini S, Maineri EP, Patriarca S, Odetti P, Cottalasso D, Marinari UM and Pronzato MA: Malondialdehyde, a lipoperoxidation-derived aldehyde, can bring about secondary oxidative damage to proteins. J Gerontol A Biol Sci Med Sci. 59:B890–B895. 2004. View Article : Google Scholar : PubMed/NCBI
24	Memişoğulari R and Bakan E: Levels of ceruloplasmin, transferring, and lipid peroxidation in serum of patients with Type 2 diabetes mellitus. J Diabetes Complications. 18:193–197. 2004.PubMed/NCBI